Activated protein C variants with normal cytoprotective but reduced anticoagulant activity

Blood

Volumn 104, Issue 6, 2004, Pages 1740-1744

  Mosnier, Laurent O ^a   Gale, Andrew J ^a   Yegneswaran, Subramanian ^a   Griffin, John H ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; DROTRECOGIN; ENDOTHELIAL CELL PROTEIN C RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; RECEPTOR PROTEIN; RECOMBINANT PROTEIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; STAUROSPORINE; UNCLASSIFIED DRUG;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BLEEDING; CELL PROTECTION; HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SEPSIS; SITE DIRECTED MUTAGENESIS;

EID: 4444331574     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-01-0110     Document Type: Article

References (29)

1. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
2. Warren BL, Eid A, Singer P, et al. High-dose anti-thrombin III in severe sepsis. A randomized controlled trial. JAMA. 2001;286:1869-1878.
3. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of titacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238-247.
4. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem. 2001;276:11199-11203.
5. Cheng T, Liu D, Griffin JH, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med. 2003;9:338-342.
6. Griffin JH, Ziokovic B, Fernandez JA. Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke. Semin Hematol. 2002;39:197-205.
7. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296:1880-1882.
8. Domotor E, Benzakour O, Griffin JH, et al. Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. Blood. 2003;101:4797-4801.
9. Coughlin SR. Thrombin signaling and protease-activated receptors. Nature. 2000;407:258-264.
10. Esmon CT, Xu J, Gu JM, et al. Endothelial protein C receptor. Thromb Haemost. 1999;82:251-258.
11. Mosnier LO, Griffin JH. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease activated receptor-1 and endothelial cell protein C receptor. Biochem J. 2003;373:65-70.
12. Quo H, Liu D, Gelbard H, et al. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron. 2004;41:563-572.
13. Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S, et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood. 2000;95:1680-1686.
14. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994;269:31869-31880.
15. Nicolaes GA, Tans G, Thomassen MC, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem. 1995;270:21158-21166.
16. Gale AJ, Heeb MJ, Griffin JH. The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites. Blood. 2000;96:585-593.
17. Gale AJ, Tsavaler A, Griffin JH. Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C. J Biol Chem. 2002;277:28836-28840.
18. Friedrich U, Nicolaes GA, Villoutreix BO, Dahlback B. Secondary substrate-binding exosite in the serine protease domain of activated protein C important for cleavage at Arg-506 but not at Arg-306 in factor Va. J Biol Chem. 2001;276:23105-23108.
19. Rezaie AR. Exosite-dependent regulation of the protein C anticoagulant pathway. Trends Cardiovasc Med. 2003;13:8-15.
20. Gale AJ, Griffin JH. Characterization of a thrombomodulin binding site on protein C and its comparison to an activated protein C binding site for factor Va. Proteins. 2004;54:433-441.
21. Mather T, Oganessyan V, Hof P, et al. The 2.8 Å crystal structure of Gla-domainless activated protein C. EMBO J. 1996;15:6822-6831.
22. Gale AJ, Sun X, Heeb MJ, Griffin JH. Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va. Protein Sci. 1997;6:132-140.
23. Van SC, Razzano P, Chao YB, et al. Characterization and novel purification of recombinant human protein C from three mammalian cell lines. Biotechnology. 1990;8:655-661.
24. Chase T, Shaw E. p-Nitrophenyl-p′-guanidino-benzoate HCI: a new active site titrant for trypsin. Biochem Biophys Res Commun. 1967;29:508-514.
25. Arosio D, Ayala YM, Di Cera E. Mutation of W215 compromises thrombin cleavage of fibrinogen, but not of PAR-1 or protein C. Biochemistry. 2000;39:8095-8101.
26. Regan LM, Mollica JS, Rezaie AR, Esmon CT. The interaction between the endothelial cell protein C receptor and protein C is dictated by the gamma-carboxyglutamic acid domain of protein C. J Biol Chem. 1997;272:26279-26284.
27. Kuliopulos A, Covic L, Seeley SK, et al. Plasmin desensitization of the PARI thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Biochemistry. 1999;38:4572-4585.
28. Kerlin BA, Van SB, Isermann BH, et al. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood. 2003;102:3085-3092.
29. Bernard GR, Macias WL, Joyce DE, et al. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care Med. 2003;7:155-163.